The Life Sciences team advised Tango Therapeutics on its oversubscribed Series B financing of $60 million led by Boxer Capital of the Tavistock Group. Cormorant Asset Management and Casdin Capital are additional new investors in the round.
Tango Therapeutics is a biotechnology company focused on discovering and delivering the next generation of targeted cancer therapies. Proceeds from the financing will advance the company’s lead program into IND-enabling studies.
The Goodwin team was led by Gabriela Morales-Rivera and Bill Collins, and included Mitch Bloom.
For more details, read the press release and articles in FierceBiotech, Xconomy and Endpoints.